Further to news relating to the PIP breast implants, Eurosurgical Ltd would like to stress that we have never supplied implants manufactured by PIP under any brand name.
Since 2002, Eurosurgical have been the exclusive UK and Ireland suppliers of implants manufactured by Silimed.
Silimed are the worlds third largest producer of implants, based in Rio de Janeiro, Brazil. Silimed implants are produced to the highest standards using only medical grade silicone supplied by Applied Silicone Inc from USA. All Silimed implants are Class III CE Marked, and manufactured in accordance with many other approved standards, ISO and FDA.
Eurosurgical would advise patients with breast implants who are uncertain of the type and manufacturer, to contact the surgeon or clinic where the implant surgery was performed.
Eurosurgical specialise in the sales and marketing
of surgical equipment, instruments and devices to the medical profession
in disciplines such as Plastic Surgery, Cosmetic & Reconstructive
Surgery, Gynaecology & Obstetrics, General Surgery and Minimally
Invasive Surgery (M.I.S) instruments.
Silimed Pure Polyurethane breast implants BioDesign Matrix The new Silimed BioDesign Matrix of polyurethane breast implants are now available from Eurosurgical Ltd. The range now features 5 unique styles of breast implants, including the exciting new Advance (Conical) shape, which is only available from Silimed and can only be considered with polyurethane foam surface technology. This implant has shown to be ideal in patients whom require a small “breast lift”, but who don’t want a mastopexy and the resulting scars. The Pure Polyurethane breast implants dramatically reduce capsular contraction, from 20% in 10-years with other types of breast implants, to less than 1%. Many other benefits can be seen with the polyurethane breast implants and with the new BioDesign matrix, the surgeon can choose from 5 breast styles, all with 4 different breast projections. For full details view the Pure web pages.
Guided Therapeutics Selects Eurosurgical to Distribute LuViva™ Advanced Cervical Scan in the United Kingdom
LuViva is designed as a follow-up test after a positive Pap test. Today, approximately 400,000 U.K. women annually are referred to more than 170 institutions for a follow-up or colposcopy examination, which often involves a biopsy of the cervix. Based on its clinical trial results, LuViva could eliminate approximately 40 percent of unnecessary follow-up procedures and could identify serious cervical disease up to two years earlier than the standard of care.
LuViva scans the cervix with light to identify cancer and pre-cancer painlessly and non-invasively. Guided Therapeutics’ patented biophotonic technology is able to distinguish between normal and diseased tissue by detecting biochemical and morphological changes at the cellular level. Unlike Pap or human papillomavirus (HPV) tests, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide immediate results at the point of care, eliminating costly and painful testing.
For more information, visit: www.guidedinc.com
